Plaque Psoriasis

A recap of the 7 phase 3 trials presented during the 2025 AAD annual meeting's late-breaking sessions.

This interview with Yamauchi highlights phase 3b findings on tildrakizumab among patients with moderate-to-severe nail psoriasis.

Andrew Alexis, MD, MPH, highlights his ‘What’s New’ talk at AAD 2025 on new practices for treating pigmentary disorders such as vitiligo.

This interview with Melinda Gooderham, MD, covers recent findings from the phase 3 ARRECTOR trial on roflumilast foam 0.3% in scalp and body psoriasis.

New data from AAD 2025 and topline results from the ICONIC program underline the potential of icotrokinra in moderate to severe plaque psoriasis.

Robert Bissonnette, MD, discusses data from the ICONIC-LEAD trial and the potential role of icotrokinra in plaque psoriasis.

This summary, featuring 4 leading experts, provides an overview of what dermatologists may look forward to during the AAD 2025 Annual Meeting.

A preview of 5 phase 3 clinical trials being presented during the AAD 2025 annual meeting's late-breaking sessions.

In this analysis, investigators demonstrated that risankizumab led to improvements in palmoplantar pustulosis (PPP) that continued through to Week 68.

These data highlight the unique burdens faced by patients with generalized pustular psoriasis (GPP) compared to those of patients with psoriasis vulgaris.

These data suggest that psoriasis treatment algorithms may benefit younger patients if they implement a step-down rather than step-up approach to biologic use.

These data suggest therapeutic modulation of IL-23 inhibitors for psoriasis in those who have shown stability may be a legitimate strategy to ensure efficacy and safety.

These findings from the POETYK-PSO long-term extension trial point to a lack of new safety concerns in the first 5 years of using deucravacitinib for psoriasis.

These data highlight deucravacitinib’s impact among patients with psoriasis who are biologic- and apremilast-naive and those with prior histories with these treatments.

In this retrospective analysis, investigators in Japan highlighted the prevalence and incidence of comorbidities in those with atopic dermatitis, psoriasis, alopecia areata, and vitiligo.

This review of January 2025 in dermatology news highlights new developments in the treatment of conditions such as psoriasis, alopecia areata, and atopic dermatitis.

This literature review points to a variety of research into differences in the diagnosis and treatment of patients with psoriasis and skin of color compared to non-skin of color patients.

These data may provide useful information for additional studies on the pathogenesis and treatments of urticaria-related psoriasis.

In this analysis, investigators explored whether dietary sodium intake was linked with psoriasis and whether any subgroups of patients were more likely to report salt-sensitive psoriasis.

These real-world, 52-week data demonstrate that deucravacitinib is effective for patients in various age brackets, though BMI has a slight impact on its efficacy.

These data highlight current applications of AI and machine learning in aesthetic medicine, looking specifically at studies graded as Level I or II.

UCB announced that a new dosing option for bimekizumab-bkzx is now available through prescription for conditions such as psoriasis, hidradenitis suppurativa, and psoriatic arthritis.

This analysis is described as the first to identify predictive factors of oral candidiasis in individuals with psoriasis who are treated with bimekizumab.

In this study, investigators pointed to existing resources available for mental health care among those with various skin conditions.

In this analysis, investigators highlighted various disease-related views and experiences dermatologists may wish to consider among Latine patients with psoriasis.